THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1 . An antibody or an antigen-binding fragment thereof, wherein said antibody binds to CS1 and inhibits immunoglobulin secretion.
2 . The antibody or the antigen-binding fragment according to claim 1 , wherein said antibody inhibits the proliferation of leukocytes.
3 . The antibody or the antigen-binding fragment according to claim 1 , wherein said antibody inhibits the proliferation of cancer cells.
4 . The antibody or the antigen-binding fragment according to claim 1 , wherein said antibody triggers cytotoxic effects on cells expressing CS1 or enhances cytotoxicity mediated by immune cells.
5 . The antibody or antigen binding fragment of claim 4 , wherein said antibody triggers ADCC-mediated cytotoxicity of cells expressing CS1.
6 . The antibody or the antigen-binding fragment according to claim 1 , wherein said antibody binds to substantially the same eptitope as the antibody produced by a hybridoma cell line having ATCC accession number PTA-5091 or a Luc63 antibody.
7 . The antibody or antigen-binding fragment according to claim 1 , wherein said antibody is produced by a hybridoma cell line having ATCC accession number PTA-5091.
8 . The antibody or the antigen-binding fragment according to claim 1 , wherein said antibody is produced by a hybridoma cell line expressing Luc63 antibody.
9 . The antibody according to claim 1 , wherein said antibody is a monoclonal antibody.
10 . The antibody according to claim 9 , wherein said monoclonal antibody is a chimeric antibody, a humanized antibody, or a fully human antibody.
11 . The antibody according to claim 1 , wherein said antibody is conjugated with a cytotoxic agent.
12 . A pharmaceutical composition comprising a pharmaceutical carrier and the antibody according to claim 1 .
13 . A method of inhibiting proliferation of CS-1 expressing cells comprising contacting said cells with an effective amount of an antagonist of CS1.
14 . The method according to claim 13 , wherein said CS-1 expressing cells are plasma cell cancer cells.
15 . The method according to claim 13 , wherein said protein is an antibody or an antigen-binding fragment that binds to CS1.
16 . The method according to claim 15 , wherein said antibody is monoclonal.
17 . A method for treating an individual with plasma cell cancer comprising administering an antagonist that specifically binds to a polypeptide encoded by SEQ ID NO:2.